Literature DB >> 12955090

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.

Yongqing Li1, Derek Liu, Dongshu Chen, Surender Kharbanda, Donald Kufe.   

Abstract

The human DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed by most carcinomas of the breast and other epithelia. The contribution of MUC1 overexpression to the malignant phenotype is, however, not known. In the present studies, we have stably expressed MUC1 in rat 3Y1 fibroblasts. MUC1-positive cells were selected from independent transfections. The results demonstrate that, as found in human carcinomas, MUC1 is expressed on the cell surface and as a complex with beta-catenin in the nucleus of the transfectants. Colony formation in soft agar demonstrates that cells expressing MUC1, but not the empty vector, exhibit anchorage-independent growth. The results also show that MUC1 expression confers tumor formation in nude mice. These findings provide the first evidence that MUC1 induces cellular transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955090      PMCID: PMC4209839          DOI: 10.1038/sj.onc.1206732

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion.

Authors:  M Yamamoto; A Bharti; Y Li; D Kufe
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

2.  Regulation of embryonic cell adhesion by the cadherin cytoplasmic domain.

Authors:  C Kintner
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

3.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

4.  Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines.

Authors:  K Kondo; N Kohno; A Yokoyama; K Hiwada
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

5.  E-cadherin germline mutations in familial gastric cancer.

Authors:  P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

6.  Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling.

Authors:  Jian Ren; Yongqing Li; Donald Kufe
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

7.  DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7.

Authors:  Yongqing Li; Wen Chen; Jian Ren; Wei-Hsuan Yu; Quan Li; Kiyotsugu Yoshida; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2003 Mar-Apr       Impact factor: 4.742

8.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

Review 9.  E-cadherin mediated adhesion system in cancer cells.

Authors:  H Shiozaki; H Oka; M Inoue; S Tamura; M Monden
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

10.  Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.

Authors:  Y Li; A Bharti; D Chen; J Gong; D Kufe
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  89 in total

1.  A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain.

Authors:  Govind Panchamoorthy; Hala Rehan; Akriti Kharbanda; Rehan Ahmad; Donald Kufe
Journal:  Hybridoma (Larchmt)       Date:  2011-12

Review 2.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 3.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

4.  MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation.

Authors:  Lei Huang; Xiaodong Liao; Michael Beckett; Yuan Li; Kum Kum Khanna; Zhugang Wang; Surender Kharbanda; Ralph Weichselbaum; Donald Kufe
Journal:  Genes Cancer       Date:  2010-03

5.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

6.  MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation.

Authors:  Li Yin; Surender Kharbanda; Donald Kufe
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

7.  Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.

Authors:  Deepak Raina; Rehan Ahmad; Maya Datt Joshi; Li Yin; Zekui Wu; Takeshi Kawano; Baldev Vasir; David Avigan; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

8.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

9.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

10.  MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.

Authors:  Deepak Raina; Rehan Ahmad; Dongshu Chen; Shailendra Kumar; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2008-12-09       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.